KR102770734B1 - Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 - Google Patents

Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 Download PDF

Info

Publication number
KR102770734B1
KR102770734B1 KR1020227017186A KR20227017186A KR102770734B1 KR 102770734 B1 KR102770734 B1 KR 102770734B1 KR 1020227017186 A KR1020227017186 A KR 1020227017186A KR 20227017186 A KR20227017186 A KR 20227017186A KR 102770734 B1 KR102770734 B1 KR 102770734B1
Authority
KR
South Korea
Prior art keywords
indol
amino
methylene
thiazol
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227017186A
Other languages
English (en)
Korean (ko)
Other versions
KR20220088750A (ko
Inventor
김양희
엄재원
서상원
최보영
Original Assignee
주식회사 진큐어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진큐어 filed Critical 주식회사 진큐어
Publication of KR20220088750A publication Critical patent/KR20220088750A/ko
Application granted granted Critical
Publication of KR102770734B1 publication Critical patent/KR102770734B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227017186A 2019-11-14 2020-11-12 Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 Active KR102770734B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190145709 2019-11-14
KR20190145709 2019-11-14
PCT/KR2020/015932 WO2021096270A1 (ko) 2019-11-14 2020-11-12 Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20220088750A KR20220088750A (ko) 2022-06-28
KR102770734B1 true KR102770734B1 (ko) 2025-02-21

Family

ID=75911395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017186A Active KR102770734B1 (ko) 2019-11-14 2020-11-12 Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물

Country Status (6)

Country Link
US (1) US12343335B2 (https=)
EP (1) EP4066832A4 (https=)
JP (1) JP7398840B2 (https=)
KR (1) KR102770734B1 (https=)
CN (1) CN114929217A (https=)
WO (1) WO2021096270A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255419A (en) * 1979-09-27 1981-03-10 Allergan Pharmaceuticals, Inc. Zinc deficiency in multiple sclerosis
JP2006513143A (ja) 2002-08-29 2006-04-20 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ タンパク質チロシンホスファターゼ阻害剤
GB0915892D0 (en) * 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
KR101324647B1 (ko) 2010-12-10 2013-11-01 한국과학기술연구원 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
EP2685976B1 (en) * 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
CN104059060B (zh) 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
KR101911785B1 (ko) 2016-08-09 2018-10-26 세종대학교 산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Journal of Immunology 197:747-760 (2016)

Also Published As

Publication number Publication date
CN114929217A (zh) 2022-08-19
EP4066832A1 (en) 2022-10-05
KR20220088750A (ko) 2022-06-28
EP4066832A4 (en) 2024-01-03
JP7398840B2 (ja) 2023-12-15
WO2021096270A1 (ko) 2021-05-20
US12343335B2 (en) 2025-07-01
JP2023501814A (ja) 2023-01-19
US20230000839A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
US20230218617A1 (en) Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
Medrano-Jiménez et al. Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism
Stackman et al. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment
JP6338531B2 (ja) 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ）
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
Wang et al. Honokiol ameliorates amyloidosis and neuroinflammation and improves cognitive impairment in Alzheimer’s disease transgenic mice
JP2011518119A (ja) ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途
Musella et al. Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis
CN109073634A (zh) 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
US20140045887A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
Chen et al. The role of the GRP78/PERK/ATF4 pathway in the ability of Gua Lou Gui Zhi decoction to attenuate apoptosis by inhibiting endoplasmic reticulum stress after ischemia-reperfusion injury
Chen et al. Exogenous hydrogen sulfide ameliorates diabetes-associated cognitive dysfunction by regulating the nrf-2/HO-1 axis and the NLRP3 inflammasome pathway in diabetic rats
US20240216316A1 (en) Dihomo-gamma linolenic acid (dgla) is a novel senolytic
US9161936B2 (en) Laquinimod for treatment of GABA mediated disorders
KR102770734B1 (ko) Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
TW202110883A (zh) 用於治療腦發炎和損傷並改善功能恢復的小窩蛋白１抗體
EP3949974A1 (en) Composition for preventing or treating neuroinflammatory disorders, comprising bee venom extract as active ingredient
US20260021167A1 (en) Compositions and methods for treating or preventing neurodegenerative diseases
Mengr Neuroprotective effects of novel anorexigenic analogs of prolactin-releasing peptide (PrRP) in models of neurodegeneration in vitro and in vivo
Yu et al. The variations of Endophilin A2-FoxO3a-autophagy signal in AngⅡ-induced dopaminergic neuron injury mouse model and By Biochanin A
KR20000023683A (ko) 티아졸리디논의 투여에 의한 신경퇴행성 질환의 치료 및 예방 방법
Leea et al. Zfra restores memory deficits in Alzheimer’s disease triple transgenic mice by blocking aggregation of TRAPPC6A∆, SH3GLB2, tau and amyloid β and inflammatory NF-κB activation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220520

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240621

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250206

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250217

End annual number: 3

Start annual number: 1

PG1601 Publication of registration